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ABSTRACT
Objectives: Retroperitoneal lymph nodes metastases occur frequently in patients with ovarian cancer. Lymphadenectomy 
increases risk of perioperative complications. In clinical practice to reduce rate of complications aortocaval lymphadenec-
tomy is omitted and solely resection of pelvic lymph nodes is performed. To establish factors affecting metastases to pelvic 
lymph nodes in advanced ovarian cancer.
Material and methods: A retrospective study among patients with serous advanced ovarian cancer (FIGO IIIB–IVB) was 
conducted at the 1st Department of Obstetrics and Gynecology, Medical University of Warsaw and Department of Gy-
necologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw. All patients underwent 
surgical treatment including pelvic lymphadenectomy between 2014 and 2017. Data including age, body mass index 
(BMI), pretreatment CA125 serum level, tumor volume, grading, one-/both-sided tumor, menopausal status, ascites were 
analysed as possible factors influencing the pelvic lymph nodes involvement. The statistical analysis was performed with 
Python software.
Results: 87 consecutive patients were eligible for the study. Metastases to pelvic lymph nodes were found in 29 (33.33%) 
patients. Pretreatment serum CA-125 concentration (652 U/mL vs 360.9 U/mL, p < 0.05) and high grade histology corre-
sponded with pelvic nodal involvement. 
Conclusions: The knowledge of factors influencing metastases to pelvic lymph nodes may help clinicians in proper coun-
selling and tailoring of therapy.
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INTRODUCTION
Ovarian cancer is the fifth leading cause of death due 
to malignancies among women in Northern America and 
the European Union [1, 2]. According to FIGO 2014 Stag-
ing System resection of retroperitoneal lymph nodes 
remains an integral part of surgical treatment [3]. Retro-
peritoneal lymph nodes involvement occurs in 40–44% of 
all patients with ovarian cancer [4, 5]. In patients without 
peritoneal dissemination lymphadenectomy is used to 
determine stage. According to LION study systematic 
lymphadenectomy in advanced ovarian cancer does not 
improve overall survival and results in extended dura-
tion of the operation, higher median blood loss, higher 
transfusion rate and more frequent serious postoperative 
complications (re-laparotomies, re-admittance, deaths 
within 60 days after surgery) [6]. However Panici et al. [7] 
found that systematic lymphadenectomy could prolong 
progression free survival, which in turn improved qual-
ity of life.
In clinical practice aortocaval lymphadenectomy is omit-
ted up to 44% of patients to reduce the rate of complica-
tions, while resection of pelvic lymph nodes is performed in 
almost every patient [5, 8, 9]. Factors affecting retroperito-
neal lymph nodes involvement were identified in previous 
studies [5, 8, 9]. However, they were established for both 
aortocaval and pelvic regions. The aim of this study is to 
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determine factors affecting metastases to pelvic lymph 
nodes in advanced ovarian cancer.
MATERIAL AND METHODS
A retrospective study was conducted at the 1st Depart-
ment of Obstetrics and Gynecology, Medical University of 
Warsaw (MUW) and Department of Gynecologic Oncol-
ogy, Maria Sklodowska Curie National Research Institute of 
Oncology (MSCNRIO), Warsaw between January 2013 and 
March 2017 among patients with serous ovarian cancer in 
advanced stage (FIGO IIIB–IVB). Intraperitoneal dissemina-
tion was confirmed in all patients during primary cytoreduc-
tive surgery. In each case, bilateral pelvic lymphadenectomy 
was conducted. Patients were divided into two groups: 
A — with metastases in pelvic lymph nodes, B — without 
pelvic lymph nodes involvement.
The exclusion criteria for primary cytoreductive surgery 
included: inoperable tumor i.e. dissemination in the porta 
hepatis or mesentery of the intestines, neoplastic infiltration 
into the aorta/inferior vena cava/pelvic main vessels esti-
mated by computed tomography or magnetic resonance.
Potential factors affecting pelvic lymph nodes involve-
ment were analysed. Data including age, body mass index 
(BMI), CA125 blood concentration, tumor volume, grading, 
one-/both-sided tumor, menarche, menopause, ascites were 
collected.
Statistical analysis was performed with Python Soft-
ware. Patients’ characteristics were presented as numbers 
of cases and percentages for categorical data, and as means 
with standard deviations (SD) for continuous data or — for 
non-continuous — medians and quartiles. The groups 
were compared by Chi-squared test for categorical vari-
ables. Statistical analysis was performed with t-Student test 
and Mann-Whitney U-test for continuous variables. The level 
of statistical significance was set at p < 0.05. 
All the procedures were conducted according to the 
Declaration of Helsinki for Medical Research involving Hu-
man Subjects. Institutional ethics committee approval was 
not required — the research is an ex-post analysis of clinical 
experience. The clinical decisions concerning the treatment 
were not influenced by the purpose of this paper.
RESULTS 
A total of 87 patients (39-MUW, 48-MSCNRIO) with serous 
ovarian cancer in advanced stage were included to the study. 
Pelvic lymph nodes involvement was confirmed in 29 (33.33%) 
patients — Group A, while in 58 women (66.67%) metasta-
ses in pelvic lymph nodes were not observed — group B. 
Data regarding patients’ characteristics are presented in 
Table 1. 82 (94.25%) patients underwent primary debulking 
surgery. 5 patients (5.75%) received neoadjuvant chemo-
therapy followed by interval cytoreduction.
In group A (n = 29) number of metastatic lymph nodes 
were: 1 in 13 patients, 2 in 6 patients, 3 in 3 patients, 4 in 
3 patients, 5 in 1 patient, 9 in 3 patients.
Patients’ mean age at surgery was 61 years (26–84). 72 of 
87 (82.76%) patients were after menopause. The majority of 
patients 72 of 87 (82.76%) were postmenopausal women. 
The most common histology was high-grade serous carci-
noma — 77/87 (88.51%). Optimal cytoreduction (< 1 cm) 
was achieved in every patient. 10 (11.49%) patients under-
went also aortocaval lymphadenectomy. 
Pretreatment CA-125 serum concentration and grading 
were related to pelvic lymph nodes involvement. Patients 
Table 1. Patients’characteristics
Variable (median/number) Total number of patients (n = 87) MUW (n = 39) MSCNRIO (n = 48)
Age [years] 62 (26–84) 63 (26–84) 61 (36–79)
Staging
IIIB 12 6 6
IIIC 69 32 37
IVA 0 0 0
IVB 6 1 5
Tumor volume [cm3] 179.59 (1.5–8704.9) 52.88 (1.5–2340) 179.59 (38–8704.9)
Number of resected lymph nodes 8 (1–28) 7 (1–14) 10.5 (2–28)
One/both sided tumor(s) 55 (63.22%) / 32 (36.78%) 28 (71.79%) / 11 (28.21%) 28 (58.33%) / 20 (41.67%)
Ascites 48 (55.17%) 23 (58.97%) 25 (52.08%)
Grading
Low 10 (11.5%) 6 (15.38%) 4 (8.3%)
High 77 (88.5%) 33 (84.62%) 44 (91.66%)
Postmenopausal status 73 (83.91%) 37 (94.87%) 36 (75%)
Pretreatment CA-125 concentration [IU/mL] 451.9 (8.18–9418) 457.6 (53.11–7316) 446.2 (8.18–9418)
BMI 27.98 (14.91–49.25) 25.22 (16.85–49.25) 28.3 (14.91–37.35)
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with pelvic lymph nodes metastases had higher pretreat-
ment median concentration of CA-125 in serum (652 IU/mL 
vs 360.9 IU/mL, p < 0.05). All patients with pelvic nodal in-
volvement were diagnosed with high-grade tumors (Tab. 2).
For other analysed variables, there was no statistically 
significant relation with pelvic lymph nodes involvement. 
However, patients in group A with present lymph node 
metastases tend to had higher median tumor volume 
compared to patients in group B (179.59 cm3 vs 52.88 cm3, 
p = 0.067).
DISCUSSION
Retroperitoneal dissemination to pelvic and aortocaval 
lymph nodes is commonly found in ovarian cancer. It results 
from lymphatic drainage pathways of the ovaries [10]. Some 
authors reported that lymph nodes invasion occurred more 
often in para-aortic than pelvic region [4, 11]. However, 
Bachmann et al. [12] found simultaneous metastases to 
both region as the most common. Other study showed that 
pelvic lymph nodes were more often affected by metastases 
than in aortocaval region [13].
Our results showed pelvic nodal involvement in 33.33% 
cases. Morice et al. [4] established that overall lymph nodes 
involvement in ovarian cancer was 44% and frequency in-
creased with stage. Fournier et al. [14] presented similar 
observations, but the ratio of metastases in primary surgery 
was 50%. In other studies, metastases to retroperitoneal 
lymph nodes in early ovarian cancer were found in 13–25% 
[4, 15], while in advanced stage were observed in 45–75% 
cases [4, 7, 16, 17]. Elective pelvic and aortocaval lymphad-
enectomy in patients with clinical stage I and II results in 
final diagnosis of stage III in 20% [4]. Compared to previous 
studies, our outcome, showing that 1/3 of patients with 
advanced OC had lymph nodes involvement, is lower. This 
discrepancy may be caused by limitation of analysis to pelvic 
lymph nodes in our study. Another reason may be different 
number of resected lymph nodes between studies.
In our study, we analysed only serous tumors regarding 
it was the histologic type associated with the most common 
pelvic and para-aortic lymph nodes involvement. Although 
Roger et al. [18] found similar frequency for lymph nodes 
involvement in different histological types of epithelial ovar-
ian cancer, other studies presented higher rate of lymph 
nodes metastases in serous tumor [8, 9, 16, 19, 20]. Zhou 
et al. showed higher risk (OR 2.728, 95% CI 1.072–6.945, 
p = 0.035) for nodal involvement in serous ovarian cancer [8]. 
Powless et al. [9] found metastases to retroperitoneal lymph 
nodes more frequent in serous tumor than in other types 
(23% vs 9%). Similar observations presented Takeshima et 
al., who demonstrated that the nodal involvement was the 
most common in serous tumors and occurs in 36.7% [21]. 
Nodal spread rarely occurs in mucinous tumor [4, 9].
Although in some studies tumor grading was not as-
sociated with lymph nodes involvement [5, 22], our results 
showed that metastases in pelvic lymph nodes were ob-
served only in high-grade tumors. Zhou et al. [8] had similar 
observations to our results. They did not find metastases to 
retroperitoneal lymph nodes in low grade tumors, while in 
grade-2 and grade-3 malignancies nodal involvement was 
54.8% and 45.2%, respectively. Other authors presented 
that the incidence of metastatic nodes was significantly 
higher in patients with poor‐differentiated tumors [9, 20, 23]. 
Kleppe et al. [24] investigated patients with early stage 
ovarian cancer. They demonstrated that nodal involvement 
in low-, middle- and high-grade ovarian cancer was 4.0%, 
16.5%, and 20.0%, respectively. The percentage of affected 
lymph nodes increases when considering an early and ad-
vanced malignancies together. Tsumura et al. [25] showed 
that incidence rates of lymph nodes metastases in grade I, 
II and III tumors were 7.1%, 31.4% and 58.3%, respectively.
In our study, we found that pretreatment CA-125 serum 
level was higher in patients with metastatic pelvic lymph 
nodes. We observed significant difference in median serum 
CA-125 among patients with and without nodal involvement 
Table 2. Comparison of patients with metastatic pelvic lymph nodes (Group A) vs patients without metastases to pelvic lymph nodes (Group B)
Variable (median/number) Group A (n = 29; 33.33%) Group B (n = 58; 66.67%) Statistics
Age [years] 62 (36–84) 63 (26–80) p = 0.822
Tumor volume [cm3] 179.59 (4.18– 767.15)
69.27 
(1.5–8704.9) p = 0.067
One-sided tumor 17 (58.62%) 38 (65.52%) p = 0.12
Ascites 18 (62.07%) 28 (48.28%) p = 0.508
Grading
Low 0 10 (15.38%)
p = 0.007
High 29 (100%) 48 (82.76%)
Postmenopausal status 21 (72.41%) 50 (86.21%) p = 0.973
Pretreatment CA-125 concentration [IU/mL] 652 (54.8–5216) 360.9 (8.18–9418) p = 0.039
BMI 24.74 (14.91–36.4) 27.98 (18.59–49.25) p = 0.11
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(652 IU/mL vs 360.9 IU/mL, p < 0.05). Zhou et al. [8] demonstrat-
ed that patients with CA-125 level of > 740 IU/mL at diagnosis 
had higher risk for lymph node metastasis compared to those 
with CA-125 level of = < 740 IU/mL (53.5% vs 22.4%, p < 0.001). 
Kim et al. [5] showed that the preoperative serum CA-125 level 
(> 535 IU/mL) was a significant predictor of lymph node me-
tastasis. Although our results are in line with other studies, we 
have concerns about the importance of serum pretreatment 
CA-125 in predicting lymph nodes involvement, especially in 
patients with advanced ovarian cancers. In such cases elevated 
serum CA-125 level may be a result of tumor volume, peritoneal 
spread or distant metastasis. Nevertheless, Powless et al. [9] 
used the cut-off value of 35 U/mL and showed that patients 
with increased preoperative serum CA-125 had positive 
lymph nodes in 22.4%. When preoperative CA-125 level was 
≤ 35 IU/mL, no metastases in lymph nodes was detected [9]. 
Sodolmus et al. found 72 and 123 IU/mL as a significant cut-off 
values for lymph nodes involvement, but the false positive 
ratio was 67.4% and 55%, respectively. Authors concluded 
that although these values may be helpful in guiding clinical 
management, the false positive ratios are too high to use as 
a screening tool for predicting lymph nodes metastases [26]. 
In opposition to the above studies, Ditto et al. [22] did not 
find any relation between lymph node metastasis and serum 
CA-125 level.
Although the patient’s age is associated with an in-
creased risk of ovarian cancer, it was not identified as risk 
factor for nodal involvement [5, 8]. Menopausal status had 
no effect on metastases to retroperitoneal lymph nodes as 
well [5, 8]. Our results were consistent with these obser-
vations. Powless et al. [9] found that ascites and bilateral 
adnexal masses were associated with an increased risk of re-
troperitoneal lymph nodes involvement. We did not observe 
these coincidence in our results. It may be a consequence 
of different characteristics of patients. Our study included 
patients only in advanced stage, while Powless et al. [9] 
analysed patients in early and advanced stage. Another 
explanation is a lack of aortocaval lymph nodes dissection 
in our study. 
Our study had several limitations. First, it had a retro-
spective character and was not randomised, therefore, we 
cannot exclude bias. Patients in our study underwent pre-
dominantly pelvic lymphadenectomy without dissection of 
aortocaval lymph nodes. Furthermore, the median number 
of resected lymph nodes in our analysis was lower than in 
other studies so proportion of metastatic lymph nodes may 
be underestimated.
CONCLUSIONS
Pretreatment serum level of CA-125 and tumor grading 
differed significantly among both analysed groups. LION 
trail showed similar OS among patients with and without 
lymphadenectomy, but decisions about lymph node status 
was done by highly-skilled surgeons. In clinical practice, in-
traoperative lymph nodes assessment by less experienced 
gynecologist/surgeon may appear challenging, especially if 
preoperative imaging is inconclusive. In such cases high pre-
treatment CA-125 serum level and serous high grade histol-
ogy of tumor may be helpful in lymphadenectomy extension.
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